Molecular Imaging

Molecular imaging (also called nuclear medicine or nuclear imaging) can image the function of cells inside the body at the molecular level. This includes the imaging modalities of positron emission computed tomography (PET) and single photon emission computed tomography (SPECT) imaging. How does PET and SPECT imaging work? Small amounts of radioactive material (radiopharmaceuticals) injected into a patient. These can use sugars or chemical traits to bond to specific cells. The radioactive material is taken up by cells that consume the sugars. The radiation emitted from inside the body is detected by photon detectors outside the body. Computers take the data to assemble images of the radiation emissions. Nuclear images may appear fuzzy or ghostly rather than the sharper resolution from MRI and CT.  But, it provides metabolic information at a cellular level, showing if there are defects in the function of the heart, areas of very high metabolic activity associated with cancer cells, or areas of inflammation, data not available from other modalities. These noninvasive imaging exams are used to diagnose cancer, heart disease, Alzheimer’s and Parkinson’s disease, bone disorders and other disorders. 

Molecular Devices Launches High-Content Imaging System with New 3D Analysis Software

Sunnyvale, Calif. – April 19, 2016 – Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the launch of its ImageXpress® Micro 4 High-Content Imaging System and revolutionary 3D image analysis capability in the latest version of MetaXpress® High-Content Image Acquisition and Analysis Software. For scientists conducting basic research or high-throughput screening, the ImageXpress System is a premiere, integrated and scalable toolset for optimal 3D image acquisition and analysis.

ABT Partners to Establish the First Radiopharmaceutical Production Facility in Cyprus

Knoxville, TN, UNITED STATES, March 18, 2016– ABT Molecular Imaging has partnered with a world-renowned oncology group to install the BG-75 Biomarker Generator System in  The Republic of Cyprus.  The BG-75 integrates a compact cyclotron, micro-chemistry, and automated quality control, to provide on-demand F-18 FDG production in one seamless solution to support the implementation of PET/CT.

New fluorine probe called a ‘major leap’ for MRI sensitivity

Radiology and biochemistry researchers at UC-San Diego say they have figured out how to dissolve and encapsulate metals inside fluorine-based droplets, in the process synthesizing a new cell-labeling probe that can, in in effect, “greatly amp up the MRI signal” for potential use in in immunotherapy, inflammation treatment and other emerging clinical applications. 

Thumbnail

Your full DNA is in your smartphone, or can be

Want to know which specific hereditary ailments you, and you alone, are susceptible to? All of them? 

Study: New peptide probes could help detect disease faster

A new advancement in real-time visualization of body tissues using molecular imaging probes could significantly increase early detection and treatment capabilities of cancer and other diseases, according to results of a study published online in Nature Communications.

Thumbnail

New FDA draft guidance covers IDE applications for neurological medical devices

The FDA has issued a new draft guidance intended to assist FDA staff and those in the healthcare industry with submitting investigational device exemption (IDE) applications to conduct clinical trials for neurological medical devices. 

Thumbnail

Twitter for clinical-trial recruitment: All but untapped, barely even explored

Of more than 1,500 tweets randomly pulled from a qualified starting cohort of more than 15,000 mentioning the term “lung cancer” over two and a half weeks in January 2015, just one lonely tweet linked to a patient recruitment website for a clinical trial.

Predicting liver tumor recurrence with immediate post-ablation FDG PET/CT

Performing PET/CT examinations using the radiotracer 18-Fluoro-deoxyglucose (FDG) immediately following localized liver tumor ablation is more effective than contrast-enhanced CT for predicting tumor recurrence, according to results of a study published online in the Journal of Nuclear Medicine.